Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.38 |
| ▸ | LIPC | P11150 | 2/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048621 | 0.92 | CTSS (0.35) | CTSSALDH1A1HTTEPHX2CYP3A4 | |
| SCHEMBL6468767 | 0.91 | CTSS (0.36) | CTSSKDM4EALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL6467381 | 0.91 | CTSS (0.36) | CTSSKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL7044831 | 0.91 | CTSS (0.36) | CTSSKDM4EALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7187232 | 0.90 | CTSS (0.38) | CTSSLIPCLIPGKDM4EMEN1 | |
| SCHEMBL6467525 | 0.89 | CTSS (0.35) | CTSSKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL6464414 | 0.87 | FAAH (0.38) | CTSSALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7043175 | 0.86 | DAGLA (0.46) | CTSSLIPCLIPGKDM4EMEN1 | |
| SCHEMBL6467366 | 0.85 | DAGLA (0.47) | LIPCLIPGKDM4EMEN1KMT2A | |
| SCHEMBL6463188 | 0.84 | DAGLA (0.48) | LIPCLIPGKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CTSS 9/4885LIPC 644/4885LIPG 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.